{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T06:50:26Z","timestamp":1791960626207,"version":"4.3.4"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"42","license":[{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2026,11,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Leukaemia arises through the stepwise transformation of healthy haematopoietic cells, yet the asymptomatic premalignant phase and its progression to overt disease remain poorly understood. To model this process, we engineered a patient-derived\n                    <jats:italic>CEBPA<\/jats:italic>\n                    mutation into Hoxb8-FL multipotent murine progenitors and transplanted them into syngeneic mice, capturing a clinically silent premalignant stage. All recipients developed overt disease after ~12 months with 100% penetrance and all acquired secondary RTK\u2013RAS mutations, often with identical amino acid changes to those in patients. Single-cell transcriptomics and phenotypic profiling showed that premalignant mutant cells adopt a plasmacytoid dendritic progenitor\u2013like state in vitro which generates both myeloid and B-lymphoid lineages during premalignancy in vivo, with individual tumours restricted to one lineage. The specificity for RTK-RAS mutations coupled with ongoing differentiation, reflects clinically relevant biological contexts thus providing a tractable model of myeloid neoplasm for mechanistic studies and drug discovery.\n                  <\/jats:p>","DOI":"10.1038\/s41388-026-03964-w","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T11:30:51Z","timestamp":1788521451000},"page":"4551-4563","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A step-wise, deterministic and fatal mouse model of myeloid neoplasm with spontaneous acquisition of patient-relevant RTK\u2013RAS mutations"],"prefix":"10.1038","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6015-3656","authenticated-orcid":false,"given":"Marija A.","family":"Zarocsinceva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6611-6108","authenticated-orcid":false,"given":"Moosa","family":"Qureshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0865-7333","authenticated-orcid":false,"given":"Nicola K.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1390-6592","authenticated-orcid":false,"given":"George","family":"Giotopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blaise","family":"Musabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine H. M.","family":"Sturgess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. S.","family":"Vijayabaskar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah J.","family":"Kinston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Asby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9490-0306","authenticated-orcid":false,"given":"David J.","family":"Adams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0312-161X","authenticated-orcid":false,"given":"Brian J. P.","family":"Huntly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando J.","family":"Calero-Nieto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6302-5705","authenticated-orcid":false,"given":"Berthold","family":"G\u00f6ttgens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,4]]},"reference":[{"key":"3964_CR1","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/s41586-021-04312-6","volume":"602","author":"N Williams","year":"2022","unstructured":"Williams N, Lee J, Mitchell E, Moore L, Baxter EJ, Hewinson J, et al. Life histories of myeloproliferative neoplasms inferred from phylogenies. Nature. 2022;602:162\u20138. https:\/\/doi.org\/10.1038\/s41586-021-04312-6.","journal-title":"Nature"},{"key":"3964_CR2","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1038\/s41591-022-01793-4","volume":"28","author":"N Sousos","year":"2022","unstructured":"Sousos N, N\u00ed Leathlobhair M, Simoglou Karali C, Louka E, Bienz N, Royston D, et al. In utero origin of myelofibrosis presenting in adult monozygotic twins. Nat Med. 2022;28:1207\u201311. https:\/\/doi.org\/10.1038\/s41591-022-01793-4.","journal-title":"Nat Med"},{"key":"3964_CR3","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1056\/nejm198708203170802","volume":"317","author":"PJ Fialkow","year":"1987","unstructured":"Fialkow PJ, Singer JW, Raskind WH, Adamson JW, Jacobson RJ, Bernstein ID, et al. Clonal development, stem-cell differentiation, and clinical remissions in acute nonlymphocytic leukemia. N Engl J Med. 1987;317:468\u201373. https:\/\/doi.org\/10.1056\/nejm198708203170802.","journal-title":"N Engl J Med"},{"key":"3964_CR4","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/nature10738","volume":"481","author":"L Ding","year":"2012","unstructured":"Ding L, Ley TJ, Larson DE, Miller CA, Koboldt DC, Welch JS, et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature. 2012;481:506\u201310. https:\/\/doi.org\/10.1038\/nature10738.","journal-title":"Nature"},{"key":"3964_CR5","doi-asserted-by":"publisher","first-page":"2202","DOI":"10.1038\/leu.2015.132","volume":"29","author":"AM Ford","year":"2015","unstructured":"Ford AM, Mansur MB, Furness CL, Van Delft FW, Okamura J, Suzuki T, et al. Protracted dormancy of pre-leukemic stem cells. Leukemia. 2015;29:2202\u20137. https:\/\/doi.org\/10.1038\/leu.2015.132.","journal-title":"Leukemia"},{"key":"3964_CR6","doi-asserted-by":"publisher","first-page":"2548","DOI":"10.1073\/pnas.1324297111","volume":"111","author":"MR Corces-Zimmerman","year":"2014","unstructured":"Corces-Zimmerman MR, Hong WJ, Weissman IL, Medeiros BC, Majeti R. Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission. Proc Natl Acad Sci USA. 2014;111:2548\u201353. https:\/\/doi.org\/10.1073\/pnas.1324297111.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3964_CR7","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1038\/nature13038","volume":"506","author":"LI Shlush","year":"2014","unstructured":"Shlush LI, Zandi S, Mitchell A, Chen WC, Brandwein JM, Gupta V, et al. Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature. 2014;506:328\u201333. https:\/\/doi.org\/10.1038\/nature13038.","journal-title":"Nature"},{"key":"3964_CR8","doi-asserted-by":"publisher","first-page":"4226","DOI":"10.1093\/emboj\/16.14.4226","volume":"16","author":"C Lavau","year":"1997","unstructured":"Lavau C, Szilvassy SJ, Slany R, Cleary ML. Immortalization and leukemic transformation of a myelomonocytic precursor by retrovirally transduced HRX-ENL. EMBO J. 1997;16:4226\u201337. https:\/\/doi.org\/10.1093\/emboj\/16.14.4226.","journal-title":"EMBO J"},{"key":"3964_CR9","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.ccr.2004.10.015","volume":"6","author":"BJP Huntly","year":"2004","unstructured":"Huntly BJP, Shigematsu H, Deguchi K, Lee BH, Mizuno S, Duclos N, et al. MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors. Cancer Cell. 2004;6:587\u201396. https:\/\/doi.org\/10.1016\/j.ccr.2004.10.015.","journal-title":"Cancer Cell"},{"key":"3964_CR10","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1038\/nmeth.2510","volume":"10","author":"V Redecke","year":"2013","unstructured":"Redecke V, Wu R, Zhou J, Finkelstein D, Chaturvedi V, High AA, et al. Hematopoietic progenitor cell lines with myeloid and lymphoid potential. Nat Methods. 2013;10:795\u2013803. https:\/\/doi.org\/10.1038\/nmeth.2510.","journal-title":"Nat Methods"},{"key":"3964_CR11","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.ccr.2010.12.012","volume":"19","author":"N Goardon","year":"2011","unstructured":"Goardon N, Marchi E, Atzberger A, Quek L, Schuh A, Soneji S, et al. Coexistence of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemia. Cancer Cell. 2011;19:138\u201352. https:\/\/doi.org\/10.1016\/j.ccr.2010.12.012.","journal-title":"Cancer Cell"},{"key":"3964_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15220-0","volume":"11","author":"S Basilico","year":"2020","unstructured":"Basilico S, Wang X, Kennedy A, Tzelepis K, Giotopoulos G, Kinston SJ, et al. Dissecting the early steps of MLL induced leukaemogenic transformation using a mouse model of AML. Nat Commun. 2020;11:1407. https:\/\/doi.org\/10.1038\/s41467-020-15220-0.","journal-title":"Nat Commun"},{"key":"3964_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-13364-2","volume":"10","author":"TP Braun","year":"2019","unstructured":"Braun TP, Okhovat M, Coblentz C, Carratt SA, Foley A, Schonrock Z, et al. Myeloid lineage enhancers drive oncogene synergy in CEBPA\/CSF3R mutant acute myeloid leukemia. Nat Commun. 2019;10:5455. https:\/\/doi.org\/10.1038\/s41467-019-13364-2.","journal-title":"Nat Commun"},{"key":"3964_CR14","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1158\/1078-0432.CCR-04-1816","volume":"11","author":"LI Lin","year":"2005","unstructured":"Lin LI, Chen CY, Lin DT, Tsay W, Tang JL, Yeh YC, et al. Characterization of CEBPA mutations in acute myeloid leukemia: Most patients with CEBPA mutations have biallelic mutations and show a distinct immunophenotype of the leukemic cells. Clinical Cancer Research. 2005;11:1372\u20139. https:\/\/doi.org\/10.1158\/1078-0432.CCR-04-1816.","journal-title":"Clinical Cancer Research"},{"key":"3964_CR15","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1046\/j.1365-2141.2003.04618.x","volume":"123","author":"J Tiesmeier","year":"2003","unstructured":"Tiesmeier J, Czwalinna A, M\u00fcller-Tidow C, Krauter J, Serve H, Heil G, et al. Evidence for allelic evolution of C\/EBPalpha mutations in acute myeloid leukaemia. Br J Haematol. 2003;123:413\u20139. https:\/\/doi.org\/10.1046\/j.1365-2141.2003.04618.x.","journal-title":"Br J Haematol"},{"key":"3964_CR16","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms. Leukemia. 2022;36:1703\u201319. https:\/\/doi.org\/10.1038\/s41375-022-01613-1.","journal-title":"Leukemia"},{"key":"3964_CR17","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345\u201377. https:\/\/doi.org\/10.1182\/blood.2022016867.","journal-title":"Blood"},{"key":"3964_CR18","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1182\/blood.2020009680","volume":"139","author":"F Taube","year":"2022","unstructured":"Taube F, Georgi JA, Kramer M, Stasik S, Middeke JM, R\u00f6llig C, et al. CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome. Blood. 2022;139:87\u2013103. https:\/\/doi.org\/10.1182\/blood.2020009680.","journal-title":"Blood"},{"key":"3964_CR19","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.exphem.2014.11.011","volume":"43","author":"K Togami","year":"2015","unstructured":"Togami K, Kitaura J, Uchida T, Inoue D, Nishimura K, Kawabata KC, et al. A C-terminal mutant of CCAAT-enhancer-binding protein \u03b1 (C\/EBP\u03b1-Cm) downregulates Csf1r, a potent accelerator in the progression of acute myeloid leukemia with C\/EBP\u03b1-Cm. Exp Hematol. 2015;43:300\u2013308.e1. https:\/\/doi.org\/10.1016\/j.exphem.2014.11.011.","journal-title":"Exp Hematol"},{"key":"3964_CR20","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1182\/blood.v94.2.560","volume":"94","author":"X Wang","year":"1999","unstructured":"Wang X, Scott E, Sawyers CL, Friedman AD. C\/EBP\u03b1 bypasses granulocyte colony-stimulating factor signals to rapidly induce PU.1 gene expression, stimulate granulocytic differentiation, and limit proliferation in 32D cl3 myeloblasts. Blood. 1999;94:560\u201371. https:\/\/doi.org\/10.1182\/blood.v94.2.560.","journal-title":"Blood"},{"key":"3964_CR21","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1182\/blood-2009-02-205443","volume":"114","author":"A Kandilci","year":"2009","unstructured":"Kandilci A, Grosveld GC. Reintroduction of CEBPA in MN1-overexpressing hematopoietic cells prevents their hyperproliferation and restores myeloid differentiation. Blood. 2009;114:1596\u2013606. https:\/\/doi.org\/10.1182\/blood-2009-02-205443.","journal-title":"Blood"},{"key":"3964_CR22","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1182\/blood-2006-10-052175","volume":"110","author":"H Schepers","year":"2007","unstructured":"Schepers H, Wierenga ATJ, Van Gosliga D, Eggen BJL, Vellenga E, Schuringa JJ. Reintroduction of C\/EBP\u03b1 in leukemic CD34+ stem\/progenitor cells impairs self-renewal and partially restores myelopoiesis. Blood. 2007;110:1317\u201325. https:\/\/doi.org\/10.1182\/blood-2006-10-052175.","journal-title":"Blood"},{"key":"3964_CR23","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1182\/blood-2002-05-1546","volume":"101","author":"J Cammenga","year":"2003","unstructured":"Cammenga J, Mulloy JC, Berguido FJ, MacGrogan D, Viale A, Nimer SD. Induction of C\/EBP\u03b1 activity alters gene expression and differentiation of human CD34+ cells. Blood. 2003;101:2206\u201314. https:\/\/doi.org\/10.1182\/blood-2002-05-1546.","journal-title":"Blood"},{"key":"3964_CR24","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/S0092-8674(01)00516-5","volume":"107","author":"BT Porse","year":"2001","unstructured":"Porse BT, Pedersen T\u00c5, Xu X, Lindberg B, Wewer UM, Friis-Hansen L, et al. E2F repression by C\/EBP\u03b1 is required for adipogenesis and granulopoiesis in vivo. Cell. 2001;107:247\u201358. https:\/\/doi.org\/10.1016\/S0092-8674(01)00516-5.","journal-title":"Cell"},{"key":"3964_CR25","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/nature12885","volume":"506","author":"B Di Stefano","year":"2014","unstructured":"Di Stefano B, Sardina JL, Van Oevelen C, Collombet S, Kallin EM, Vicent GP, et al. C\/EBP\u03b1 poises B cells for rapid reprogramming into induced pluripotent stem cells. Nature. 2014;506:235\u20139. https:\/\/doi.org\/10.1038\/nature12885.","journal-title":"Nature"},{"key":"3964_CR26","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1158\/0008-5472.CAN-11-2612","volume":"72","author":"IA Prior","year":"2012","unstructured":"Prior IA, Lewis PD, Mattos C. A comprehensive survey of RAS mutations in cancer. Cancer Res. 2012;72:2457\u201367. https:\/\/doi.org\/10.1158\/0008-5472.CAN-11-2612.","journal-title":"Cancer Res"},{"key":"3964_CR27","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.1158\/0008-5472.CAN-19-3682","volume":"80","author":"IA Prior","year":"2020","unstructured":"Prior IA, Hood FE, Hartley JL. The frequency of RAS mutations in cancer. Cancer Res. 2020;80:2969\u201374. https:\/\/doi.org\/10.1158\/0008-5472.CAN-19-3682.","journal-title":"Cancer Res"},{"key":"3964_CR28","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1182\/blood-2008-04-152157","volume":"113","author":"JW Tyner","year":"2009","unstructured":"Tyner JW, Erickson H, Deininger MWN, Willis SG, Eide CA, Levine RL, et al. High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients. Blood. 2009;113:1749\u201355. https:\/\/doi.org\/10.1182\/blood-2008-04-152157.","journal-title":"Blood"},{"key":"3964_CR29","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1182\/BLOODADVANCES.2021004631","volume":"5","author":"S Stasik","year":"2021","unstructured":"Stasik S, Eckardt JN, Kramer M, R\u00f6llig C, Kr\u00e4mer A, Scholl S, et al. Impact of PTPN11 mutations on clinical outcome analyzed in 1529 patients with acute myeloid leukemia. Blood Adv. 2021;5:3279\u201389. https:\/\/doi.org\/10.1182\/BLOODADVANCES.2021004631.","journal-title":"Blood Adv"},{"key":"3964_CR30","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1038\/s41375-020-0920-z","volume":"35","author":"M Alfayez","year":"2021","unstructured":"Alfayez M, Issa GC, Patel KP, Wang F, Wang X, Short NJ, et al. The Clinical impact of PTPN11 mutations in adults with acute myeloid leukemia. Leukemia. 2021;35:691\u2013700. https:\/\/doi.org\/10.1038\/s41375-020-0920-z.","journal-title":"Leukemia"},{"key":"3964_CR31","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1182\/blood-2003-11-3876","volume":"104","author":"M Tartaglia","year":"2004","unstructured":"Tartaglia M, Martinelli S, Cazzaniga G, Cordeddu V, Iavarone I, Spinelli M, et al. Genetic evidence for lineage-related and differentiation stage-related contribution of somatic PTPN11 mutations to leukemogenesis in childhood acute leukemia. Blood. 2004;104:307\u2013313. https:\/\/doi.org\/10.1182\/blood-2003-11-3876.","journal-title":"Blood"},{"key":"3964_CR32","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1182\/blood-2005-02-0531","volume":"106","author":"CP Kratz","year":"2005","unstructured":"Kratz CP, Niemeyer CM, Castleberry RP, Cetin M, Bergstr\u00e4sser E, Emanuel PD, et al. The mutational spectrum of PTPN11 in juvenile myelomonocytic leukemia and Noonan syndrome\/myeloproliferative disease. Blood. 2005;106:2183\u20132185. https:\/\/doi.org\/10.1182\/blood-2005-02-0531.","journal-title":"Blood"},{"key":"3964_CR33","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/ng1156","volume":"34","author":"M Tartaglia","year":"2003","unstructured":"Tartaglia M, Niemeyer CM, Fragale A, Song X, Buechner J, Jung A, et al. Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. Nat Genet. 2003;34:148\u201350. https:\/\/doi.org\/10.1038\/ng1156.","journal-title":"Nat Genet"},{"key":"3964_CR34","doi-asserted-by":"publisher","first-page":"5477","DOI":"10.1182\/blood-2006-09-046649","volume":"109","author":"K Matsuda","year":"2007","unstructured":"Matsuda K, Shimada A, Yoshida N, Ogawa A, Watanabe A, Yajima S, et al. Spontaneous improvement of hematologic abnormalities in patients having juvenile myelomonocytic leukemia with specific RAS mutations. Blood. 2007;109:5477\u201380. https:\/\/doi.org\/10.1182\/blood-2006-09-046649.","journal-title":"Blood"},{"key":"3964_CR35","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1016\/j.jpeds.2013.01.003","volume":"162","author":"M Kato","year":"2013","unstructured":"Kato M, Yasui N, Seki M, Kishimoto H, Sato-Otsubo A, Hasegawa D, et al. Aggressive transformation of juvenile myelomonocytic leukemia associated with duplication of oncogenic KRAS due to acquired uniparental disomy. J Pediatr. 2013;162:1285\u201388.e1. https:\/\/doi.org\/10.1016\/j.jpeds.2013.01.003.","journal-title":"J Pediatr"},{"key":"3964_CR36","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1182\/blood-2007-09-111831","volume":"111","author":"C Flotho","year":"2008","unstructured":"Flotho C, Kratz CP, Bergstr\u00e4sser E, Hasle H, Star\u00fd J, Trebo M, et al. Genotype-phenotype correlation in cases of juvenile myelomonocytic leukemia with clonal RAS mutations. Blood. 2008;111:966\u20137. https:\/\/doi.org\/10.1182\/blood-2007-09-111831.","journal-title":"Blood"},{"key":"3964_CR37","doi-asserted-by":"publisher","unstructured":"Mu\u00f1oz-Maldonado C, Zimmer Y, Medov\u00e1 M. A comparative analysis of individual RAS mutations in cancer biology. Front Oncol 2019;9. https:\/\/doi.org\/10.3389\/fonc.2019.01088.","DOI":"10.3389\/fonc.2019.01088"},{"key":"3964_CR38","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/nejmoa1516192","volume":"374","author":"E Papaemmanuil","year":"2016","unstructured":"Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374:2209\u201321. https:\/\/doi.org\/10.1056\/nejmoa1516192.","journal-title":"N Engl J Med"},{"key":"3964_CR39","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/s41586-024-08137-x","volume":"636","author":"J Sango","year":"2024","unstructured":"Sango J, Carcamo S, Sirenko M, Maiti A, Mansour H, Ulukaya G, et al. RAS-mutant leukaemia stem cells drive clinical resistance to venetoclax. Nature. 2024;636:241\u201350.","journal-title":"Nature"},{"key":"3964_CR40","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.3324\/haematol.2018.205351","volume":"104","author":"C Di Genua","year":"2019","unstructured":"Di Genua C, Norfo R, Rodriguez-Meira A, Wen WX, Drissen R, Booth CAG, et al. Cell-intrinsic depletion of Aml1-ETO-expressing pre-leukemic hematopoietic stem cells by K-Ras activating mutation. Haematologica. 2019;104:2215\u201324. https:\/\/doi.org\/10.3324\/haematol.2018.205351.","journal-title":"Haematologica"},{"key":"3964_CR41","doi-asserted-by":"publisher","first-page":"4783","DOI":"10.1182\/bloodadvances.2021005117","volume":"5","author":"A Wintering","year":"2021","unstructured":"Wintering A, Dvorak CC, Stieglitz E, Loh ML. Juvenile myelomonocytic leukemia in the molecular era: A clinician\u2019s guide to diagnosis, risk stratification, and treatment. Blood Adv. 2021;5:4783\u201393. https:\/\/doi.org\/10.1182\/bloodadvances.2021005117.","journal-title":"Blood Adv"},{"key":"3964_CR42","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/s41375-019-0549-y","volume":"34","author":"AK Chao","year":"2020","unstructured":"Chao AK, Meyer JA, Lee AG, Hecht A, Tarver T, Van Ziffle J, et al. Fusion driven JMML: a novel CCDC88C\u2013FLT3 fusion responsive to sorafenib identified by RNA sequencing. Leukemia. 2020;34:662\u20136. https:\/\/doi.org\/10.1038\/s41375-019-0549-y.","journal-title":"Leukemia"},{"key":"3964_CR43","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1002\/pbc.20176","volume":"44","author":"EJ Gratias","year":"2005","unstructured":"Gratias EJ, Liu YL, Meleth S, Castleberry RP, Emanuel PD. Activating FLT3 mutations are rare in children with juvenile myelomonocytic leukemia. Pediatr Blood Cancer. 2005;44:142\u20136. https:\/\/doi.org\/10.1002\/pbc.20176.","journal-title":"Pediatr Blood Cancer"},{"key":"3964_CR44","doi-asserted-by":"publisher","unstructured":"Nabarro S, Thrasher AJ, Kempski H, Amrolia P, Anderson J. Generation of immunostimulatory dendritic cells from the malignant clone in patients with juvenile myelomonocytic leukemia [1910-1912]. Leukemia. 2003;17. https:\/\/doi.org\/10.1038\/sj.leu.2403059.","DOI":"10.1038\/sj.leu.2403059"},{"key":"3964_CR45","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1038\/sj.thj.6200192","volume":"3","author":"D Longoni","year":"2002","unstructured":"Longoni D, D'Amico G, Gaipa G, Bernasconi S, Vulcano M, Onnis P, et al. Commitment of juvenile myelo-monocytic (JMML) leukemic cells to spontaneously differentiate into dendritic cells. Hematol J. 2002;3:302\u201310. https:\/\/doi.org\/10.1038\/sj.thj.6200192.","journal-title":"Hematol J"},{"key":"3964_CR46","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.humpath.2017.03.025","volume":"68","author":"H Meyerson","year":"2017","unstructured":"Meyerson H, Awadallah A, Blidaru G, Osei E, Schlegelmilch J, Egler R, et al. Juvenile myelomonocytic leukemia with prominent CD141+ myeloid dendritic cell differentiation. Hum Pathol. 2017;68:147\u201353. https:\/\/doi.org\/10.1016\/j.humpath.2017.03.025.","journal-title":"Hum Pathol"},{"key":"3964_CR47","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.leukres.2008.08.022","volume":"33","author":"RJ Chan","year":"2009","unstructured":"Chan RJ, Cooper T, Kratz CP, Weiss B, Loh ML. Juvenile myelomonocytic leukemia: a report from the 2nd International JMML Symposium. Leuk Res. 2009;33:355\u201362. https:\/\/doi.org\/10.1016\/j.leukres.2008.08.022.","journal-title":"Leuk Res"},{"key":"3964_CR48","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1182\/asheducation-2018.1.307","volume":"2018","author":"CM Niemeyer","year":"2018","unstructured":"Niemeyer CM. JMML genomics and decisions. Hematology. 2018;2018:307\u201312. https:\/\/doi.org\/10.1182\/asheducation-2018.1.307.","journal-title":"Hematology"},{"key":"3964_CR49","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1038\/s41375-019-0662-y","volume":"34","author":"A Caye","year":"2020","unstructured":"Caye A, Rouault-Pierre K, Strullu M, Lainey E, Abarrategi A, Fenneteau O, et al. Despite mutation acquisition in hematopoietic stem cells, JMML-propagating cells are not always restricted to this compartment. Leukemia. 2020;34:1658\u201368. https:\/\/doi.org\/10.1038\/s41375-019-0662-y.","journal-title":"Leukemia"},{"key":"3964_CR50","unstructured":"Hartmann M, Sch\u00f6nung M, Rajak J, Maurer V, Hai L, Bauer K, et al. Oncogenic RAS-pathway activation drives oncofetal reprogramming and creates therapeutic vulnerabilities in juvenile myelomonocytic leukemia. 2023. https:\/\/www.biorxiv.org\/content\/10.1101\/2023.10.27.563754v1."},{"key":"3964_CR51","doi-asserted-by":"publisher","first-page":"5557.","DOI":"10.1182\/blood.v128.22.5557.5557","volume":"128","author":"SK Hashmi","year":"2016","unstructured":"Hashmi SK, Punia JN, Gaikwad AS, Fisher KE, Roy A, Lopez-Terrada DH, et al. Aberrant precursor B lymphoid blast population in a patient with juvenile myelomonocytic leukemia. Blood. 2016;128:5557. https:\/\/doi.org\/10.1182\/blood.v128.22.5557.5557.","journal-title":"Blood"},{"key":"3964_CR52","first-page":"903","volume":"8","author":"RC Lau","year":"1994","unstructured":"Lau RC, Squire J, Brisson L, Kamel-Reid S, Grunberger T, Dub\u00e9 I, et al. Lymphoid blast crisis of B-lineage phenotype with monosomy 7 in a patient with juvenile chronic myelogenous leukemia (JCML). Leukemia. 1994;8:903\u20138.","journal-title":"Leukemia"},{"key":"3964_CR53","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/j.trecan.2023.07.010","volume":"9","author":"MN Zeissig","year":"2023","unstructured":"Zeissig MN, Ashwood LM, Kondrashova O, Sutherland KD. Next batter up! Targeting cancers with KRAS-G12D mutations. Trends Cancer. 2023;9:955\u201367. https:\/\/doi.org\/10.1016\/j.trecan.2023.07.010.","journal-title":"Trends Cancer"},{"key":"3964_CR54","doi-asserted-by":"publisher","first-page":"386.","DOI":"10.1038\/s41392-021-00780-4","volume":"6","author":"L Huang","year":"2021","unstructured":"Huang L, Guo Z, Wang F, Fu L. KRAS mutation: from undruggable to druggable in cancer. Signal Transduct Target Ther. 2021;6:386. https:\/\/doi.org\/10.1038\/s41392-021-00780-4.","journal-title":"Signal Transduct Target Ther"},{"key":"3964_CR55","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1038\/leu.2014.239","volume":"29","author":"K Sakashita","year":"2015","unstructured":"Sakashita K, Kato I, Daifu T, Saida S, Hiramatsu H, Nishinaka Y, et al. In vitro expansion of CD34+ CD38- cells under stimulation with hematopoietic growth factors on AGM-S3 cells in juvenile myelomonocytic leukemia. Leukemia. 2015;29:606\u201314. https:\/\/doi.org\/10.1038\/leu.2014.239.","journal-title":"Leukemia"},{"key":"3964_CR56","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1038\/nprot.2014.006","volume":"9","author":"S Picelli","year":"2014","unstructured":"Picelli S, Faridani OR, Bj\u00f6rklund \u00c5K, Winberg G, Sagasser S, Sandberg R. Full-length RNA-seq from single cells using Smart-seq2. Nat Protoc. 2014;9:171\u201381. https:\/\/doi.org\/10.1038\/nprot.2014.006.","journal-title":"Nat Protoc"},{"key":"3964_CR57","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05347-6","volume":"9","author":"JW Bagnoli","year":"2018","unstructured":"Bagnoli JW, Ziegenhain C, Janjic A, Wange LE, Vieth B, Parekh S, et al. Sensitive and powerful single-cell RNA sequencing using mcSCRB-seq. Nat Commun. 2018;9:2937. https:\/\/doi.org\/10.1038\/s41467-018-05347-6.","journal-title":"Nat Commun"},{"key":"3964_CR58","doi-asserted-by":"crossref","unstructured":"Kucinski I, Wilson NK, Hannah R, Kinston SJ, Cauchy P, Lenaerts A, et al. Interactions between lineage-associated transcription factors govern haematopoietic progenitor states. EMBO J. 2020;39: 10.15252\/embj.2020104983.","DOI":"10.15252\/embj.2020104983"},{"key":"3964_CR59","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-017-1382-0","volume":"19","author":"FA Wolf","year":"2018","unstructured":"Wolf FA, Angerer P, Theis FJ. SCANPY: Large-scale single-cell gene expression data analysis. Genome Biol. 2018;19:15. https:\/\/doi.org\/10.1186\/s13059-017-1382-0.","journal-title":"Genome Biol"},{"key":"3964_CR60","unstructured":"Li H. Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM. 2013. http:\/\/arxiv.org\/abs\/1303.3997."},{"key":"3964_CR61","unstructured":"Auwera G van der, O\u2019Connor BD. Genomics in the cloud: using Docker, GATK, and WDL in Terra. First edition. O\u2019Reilly Media: Sebastopol, CA. 2020."},{"key":"3964_CR62","doi-asserted-by":"publisher","first-page":"e164.","DOI":"10.1093\/nar\/gkq603","volume":"38","author":"K Wang","year":"2010","unstructured":"Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 2010;38:e164. https:\/\/doi.org\/10.1093\/nar\/gkq603.","journal-title":"Nucleic Acids Res"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03964-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03964-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03964-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T06:38:55Z","timestamp":1791959935000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03964-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,4]]},"references-count":62,"journal-issue":{"issue":"42","published-print":{"date-parts":[[2026,11,4]]}},"alternative-id":["3964"],"URL":"https:\/\/doi.org\/10.1038\/s41388-026-03964-w","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,4]]},"assertion":[{"value":"20 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"FJC-N performed the work described in this manuscript during his employment at the Stem Cell Institute, but is now an employee of Astra Zeneca.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}